@mattiasmandorfer.bsky.social
😀🇦🇹 multisociety (gastroenterology & hepatology, diabetology & obesity) consensus on MASLD (& MetALD!)
🤝Well-aligned with @easlnews.bsky.social CPGs
😟Reimbursement currently restricted to semaglutide for T2DM
🤔Reimbursement in your country?
🖇️: rdcu.be/eLAde
#LiverSky @georg-semmler.bsky.social
🤝Well-aligned with @easlnews.bsky.social CPGs
😟Reimbursement currently restricted to semaglutide for T2DM
🤔Reimbursement in your country?
🖇️: rdcu.be/eLAde
#LiverSky @georg-semmler.bsky.social
November 8, 2025 at 3:02 AM
😀🇦🇹 multisociety (gastroenterology & hepatology, diabetology & obesity) consensus on MASLD (& MetALD!)
🤝Well-aligned with @easlnews.bsky.social CPGs
😟Reimbursement currently restricted to semaglutide for T2DM
🤔Reimbursement in your country?
🖇️: rdcu.be/eLAde
#LiverSky @georg-semmler.bsky.social
🤝Well-aligned with @easlnews.bsky.social CPGs
😟Reimbursement currently restricted to semaglutide for T2DM
🤔Reimbursement in your country?
🖇️: rdcu.be/eLAde
#LiverSky @georg-semmler.bsky.social
📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)
👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3
🖇️ for explanation: authors.elsevier.com/sd/article/S...
👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3
🖇️ for explanation: authors.elsevier.com/sd/article/S...
October 3, 2025 at 7:06 AM
📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)
👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3
🖇️ for explanation: authors.elsevier.com/sd/article/S...
👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3
🖇️ for explanation: authors.elsevier.com/sd/article/S...
📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)
👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3
🖇️ for explanation: authors.elsevier.com/sd/article/S...
👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3
🖇️ for explanation: authors.elsevier.com/sd/article/S...
October 3, 2025 at 7:03 AM
📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)
👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3
🖇️ for explanation: authors.elsevier.com/sd/article/S...
👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3
🖇️ for explanation: authors.elsevier.com/sd/article/S...
@bavenocoop.bsky.social visiting the Japanese Society of Portal Hypertension
👀 at our auditorium
🙏 incredible hospitality
👉 See our 🇯🇵 friends at Baveno VIII
👀 at our auditorium
🙏 incredible hospitality
👉 See our 🇯🇵 friends at Baveno VIII
September 12, 2025 at 9:53 AM
@bavenocoop.bsky.social visiting the Japanese Society of Portal Hypertension
👀 at our auditorium
🙏 incredible hospitality
👉 See our 🇯🇵 friends at Baveno VIII
👀 at our auditorium
🙏 incredible hospitality
👉 See our 🇯🇵 friends at Baveno VIII
Reposted
I am very sad. My mentor and friend, Jaume Bosch, just has passed away. Thanks for everything, I will miss you. I would always remember our last day together celebrating a journey we begin together @hospitalclinic.bsky.social @idibaps.bsky.social
July 15, 2025 at 6:02 PM
I am very sad. My mentor and friend, Jaume Bosch, just has passed away. Thanks for everything, I will miss you. I would always remember our last day together celebrating a journey we begin together @hospitalclinic.bsky.social @idibaps.bsky.social
Reposted
🖤 With deep sorrow, we announce the passing of Prof. Dr. Jaime Bosch, President of the Baveno Cooperation.
A brilliant scientist, inspiring leader, and dear friend. His immense legacy in hepatology will endure.
Rest in peace, Jaime
A brilliant scientist, inspiring leader, and dear friend. His immense legacy in hepatology will endure.
Rest in peace, Jaime
July 16, 2025 at 7:11 AM
🖤 With deep sorrow, we announce the passing of Prof. Dr. Jaime Bosch, President of the Baveno Cooperation.
A brilliant scientist, inspiring leader, and dear friend. His immense legacy in hepatology will endure.
Rest in peace, Jaime
A brilliant scientist, inspiring leader, and dear friend. His immense legacy in hepatology will endure.
Rest in peace, Jaime
Monitoring resmetirom by LSM - asking for the moon?
Oftentimes mentioned but even more often forgotten:
❗️Random variation of LSM by VCTE exceeds 25%
👉🔽 LSM >25% often by chance, same for 'unchanged' or increases
👉No substitute for clinical judgement
#LiverSky @georg-semmler.bsky.social
🔗👇
Oftentimes mentioned but even more often forgotten:
❗️Random variation of LSM by VCTE exceeds 25%
👉🔽 LSM >25% often by chance, same for 'unchanged' or increases
👉No substitute for clinical judgement
#LiverSky @georg-semmler.bsky.social
🔗👇
May 20, 2025 at 6:24 PM
Monitoring resmetirom by LSM - asking for the moon?
Oftentimes mentioned but even more often forgotten:
❗️Random variation of LSM by VCTE exceeds 25%
👉🔽 LSM >25% often by chance, same for 'unchanged' or increases
👉No substitute for clinical judgement
#LiverSky @georg-semmler.bsky.social
🔗👇
Oftentimes mentioned but even more often forgotten:
❗️Random variation of LSM by VCTE exceeds 25%
👉🔽 LSM >25% often by chance, same for 'unchanged' or increases
👉No substitute for clinical judgement
#LiverSky @georg-semmler.bsky.social
🔗👇
Reposted
How often do u get asked to “clear” patients w/cirrhosis for surgery?
How about “just” being on board?
#liversky
Well, if u want to get on board, here is your next read 👇🏼
Guidelines on abdominal surgery in patients w/cirrhosis
@jhepatology.bsky.social
www.journal-of-hepatology.eu/article/S016...
How about “just” being on board?
#liversky
Well, if u want to get on board, here is your next read 👇🏼
Guidelines on abdominal surgery in patients w/cirrhosis
@jhepatology.bsky.social
www.journal-of-hepatology.eu/article/S016...
May 13, 2025 at 1:59 PM
How often do u get asked to “clear” patients w/cirrhosis for surgery?
How about “just” being on board?
#liversky
Well, if u want to get on board, here is your next read 👇🏼
Guidelines on abdominal surgery in patients w/cirrhosis
@jhepatology.bsky.social
www.journal-of-hepatology.eu/article/S016...
How about “just” being on board?
#liversky
Well, if u want to get on board, here is your next read 👇🏼
Guidelines on abdominal surgery in patients w/cirrhosis
@jhepatology.bsky.social
www.journal-of-hepatology.eu/article/S016...
📢 First @easlnews.bsky.social CPG on surgery in cirrhosis presented today together with the one on TIPS!
🤝 See you at 10:30 Erlinger Room!
@bavenocoop.bsky.social #LiverSky
🤝 See you at 10:30 Erlinger Room!
@bavenocoop.bsky.social #LiverSky
🆕CPG in press❕
EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease
Find it here👉https://bit.ly/3GM9EEB
#LiverSky
@easlnews.bsky.social
EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease
Find it here👉https://bit.ly/3GM9EEB
#LiverSky
@easlnews.bsky.social
May 10, 2025 at 6:16 AM
📢 First @easlnews.bsky.social CPG on surgery in cirrhosis presented today together with the one on TIPS!
🤝 See you at 10:30 Erlinger Room!
@bavenocoop.bsky.social #LiverSky
🤝 See you at 10:30 Erlinger Room!
@bavenocoop.bsky.social #LiverSky
👏
Standing ovations for @bavenocoop.bsky.social's @docberza.bsky.social at the @easlnews.bsky.social Community Award presentation.
Chapeau! What a wonderful person!
#LiverSky
Standing ovations for @bavenocoop.bsky.social's @docberza.bsky.social at the @easlnews.bsky.social Community Award presentation.
Chapeau! What a wonderful person!
#LiverSky
May 9, 2025 at 9:44 AM
👏
Standing ovations for @bavenocoop.bsky.social's @docberza.bsky.social at the @easlnews.bsky.social Community Award presentation.
Chapeau! What a wonderful person!
#LiverSky
Standing ovations for @bavenocoop.bsky.social's @docberza.bsky.social at the @easlnews.bsky.social Community Award presentation.
Chapeau! What a wonderful person!
#LiverSky
Thirteen years ago when I was still an M.D. student, I was invited for my first oral presentation at an @easlnews.bsky.social event.
🙏 to EASL for inspiration, education & support throughout this journey as well as to my mentors & friends! @bavenocoop.bsky.social #LiverSky
🙏 to EASL for inspiration, education & support throughout this journey as well as to my mentors & friends! @bavenocoop.bsky.social #LiverSky
May 7, 2025 at 2:04 PM
Thirteen years ago when I was still an M.D. student, I was invited for my first oral presentation at an @easlnews.bsky.social event.
🙏 to EASL for inspiration, education & support throughout this journey as well as to my mentors & friends! @bavenocoop.bsky.social #LiverSky
🙏 to EASL for inspiration, education & support throughout this journey as well as to my mentors & friends! @bavenocoop.bsky.social #LiverSky
‼️Following first hepatic decompensation, patients with severe #AATD have a higher risk of complications vs. other aetiologies
👉Early listing for liver transplantation. #LiverSky
🔗https://doi.org/10.1016/j.jhepr.2024.101308
@easlnews.bsky.social @jhepatology.bsky.social
👉Early listing for liver transplantation. #LiverSky
🔗https://doi.org/10.1016/j.jhepr.2024.101308
@easlnews.bsky.social @jhepatology.bsky.social
March 21, 2025 at 3:19 PM
‼️Following first hepatic decompensation, patients with severe #AATD have a higher risk of complications vs. other aetiologies
👉Early listing for liver transplantation. #LiverSky
🔗https://doi.org/10.1016/j.jhepr.2024.101308
@easlnews.bsky.social @jhepatology.bsky.social
👉Early listing for liver transplantation. #LiverSky
🔗https://doi.org/10.1016/j.jhepr.2024.101308
@easlnews.bsky.social @jhepatology.bsky.social
Have you ever screened 25 patients for a single trial and randomized nearly as many?
Vienna Hepatic Hemodynamic Lab advancing drug development for portal hypertension. Eager to see results ...
#LiverSky @bavenocoop.bsky.social
Vienna Hepatic Hemodynamic Lab advancing drug development for portal hypertension. Eager to see results ...
#LiverSky @bavenocoop.bsky.social
March 14, 2025 at 3:34 PM
Have you ever screened 25 patients for a single trial and randomized nearly as many?
Vienna Hepatic Hemodynamic Lab advancing drug development for portal hypertension. Eager to see results ...
#LiverSky @bavenocoop.bsky.social
Vienna Hepatic Hemodynamic Lab advancing drug development for portal hypertension. Eager to see results ...
#LiverSky @bavenocoop.bsky.social
Conversation with the Customs employee at the airport when entering the U.S. for a 1-day meeting:
When is your flight back? - Tomorrow. - So they pay you well. - No, I'm in academia. - Oh, so they own you. 😋
When is your flight back? - Tomorrow. - So they pay you well. - No, I'm in academia. - Oh, so they own you. 😋
March 11, 2025 at 8:59 PM
Conversation with the Customs employee at the airport when entering the U.S. for a 1-day meeting:
When is your flight back? - Tomorrow. - So they pay you well. - No, I'm in academia. - Oh, so they own you. 😋
When is your flight back? - Tomorrow. - So they pay you well. - No, I'm in academia. - Oh, so they own you. 😋
@bavenocoop.bsky.social Research Committee Baveno VIII Pre-Symposium, here we go!
👍 103 members watching online
👉 High interest in designing clinical studies on PH.
#liversky
👍 103 members watching online
👉 High interest in designing clinical studies on PH.
#liversky
March 5, 2025 at 3:50 PM
@bavenocoop.bsky.social Research Committee Baveno VIII Pre-Symposium, here we go!
👍 103 members watching online
👉 High interest in designing clinical studies on PH.
#liversky
👍 103 members watching online
👉 High interest in designing clinical studies on PH.
#liversky
I had the privilege to visit two top liver destinations in 🇪🇺 in the last couple of days - 🙏 enormous hospitality
🇨🇭Bern @docberza.bsky.social et al
🇮🇹Padova Alberto Zanetto et al
👀Summary slides attached!
#liversky
🇨🇭Bern @docberza.bsky.social et al
🇮🇹Padova Alberto Zanetto et al
👀Summary slides attached!
#liversky
February 26, 2025 at 11:00 PM
I had the privilege to visit two top liver destinations in 🇪🇺 in the last couple of days - 🙏 enormous hospitality
🇨🇭Bern @docberza.bsky.social et al
🇮🇹Padova Alberto Zanetto et al
👀Summary slides attached!
#liversky
🇨🇭Bern @docberza.bsky.social et al
🇮🇹Padova Alberto Zanetto et al
👀Summary slides attached!
#liversky
Challenge for #liversky :
Monitoring regression/progression on resmetirom & deciding on alternative treatments
▶️ AASLD provided guidance
▶️ We commented on the role of LSM: doi.org/10.1097/HEP....
‼️ Random variation in LSM >25%
‼️ Consider overall medical benefit (e.g., GLP-1)
Monitoring regression/progression on resmetirom & deciding on alternative treatments
▶️ AASLD provided guidance
▶️ We commented on the role of LSM: doi.org/10.1097/HEP....
‼️ Random variation in LSM >25%
‼️ Consider overall medical benefit (e.g., GLP-1)
February 15, 2025 at 10:49 AM
Challenge for #liversky :
Monitoring regression/progression on resmetirom & deciding on alternative treatments
▶️ AASLD provided guidance
▶️ We commented on the role of LSM: doi.org/10.1097/HEP....
‼️ Random variation in LSM >25%
‼️ Consider overall medical benefit (e.g., GLP-1)
Monitoring regression/progression on resmetirom & deciding on alternative treatments
▶️ AASLD provided guidance
▶️ We commented on the role of LSM: doi.org/10.1097/HEP....
‼️ Random variation in LSM >25%
‼️ Consider overall medical benefit (e.g., GLP-1)
👋 Bluesky
📰 Review: Non-invasive assessment of portal hypertension: Liver stiffness and beyond
@docberza.bsky.social & @juanabraldes.bsky.social summarising the evidence for the upcoming @bavenocoop.bsky.social VIII in @jhepatology.bsky.social Reports
🔗https://doi.org/10.1016/j.jhepr.2024.101300
📰 Review: Non-invasive assessment of portal hypertension: Liver stiffness and beyond
@docberza.bsky.social & @juanabraldes.bsky.social summarising the evidence for the upcoming @bavenocoop.bsky.social VIII in @jhepatology.bsky.social Reports
🔗https://doi.org/10.1016/j.jhepr.2024.101300
February 13, 2025 at 11:18 PM
👋 Bluesky
📰 Review: Non-invasive assessment of portal hypertension: Liver stiffness and beyond
@docberza.bsky.social & @juanabraldes.bsky.social summarising the evidence for the upcoming @bavenocoop.bsky.social VIII in @jhepatology.bsky.social Reports
🔗https://doi.org/10.1016/j.jhepr.2024.101300
📰 Review: Non-invasive assessment of portal hypertension: Liver stiffness and beyond
@docberza.bsky.social & @juanabraldes.bsky.social summarising the evidence for the upcoming @bavenocoop.bsky.social VIII in @jhepatology.bsky.social Reports
🔗https://doi.org/10.1016/j.jhepr.2024.101300